Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Fiche publication
Date publication
avril 2018
Journal
The New England journal of medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe
Tous les auteurs :
Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B,
Lien Pubmed
Résumé
Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced renal-cell carcinoma.
Mots clés
Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, administration & dosage, Antineoplastic Agents, Immunological, administration & dosage, Antineoplastic Combined Chemotherapy Protocols, adverse effects, Carcinoma, Renal Cell, drug therapy, Disease-Free Survival, Humans, Indoles, administration & dosage, Ipilimumab, administration & dosage, Kidney Neoplasms, drug therapy, Male, Middle Aged, Pyrroles, administration & dosage, Quality of Life, Risk, Survival Analysis, Survival Rate
Référence
N. Engl. J. Med.. 2018 04 5;378(14):1277-1290